Cantor Fitzgerald Begins Coverage on InflaRx (NASDAQ:IFRX)

Cantor Fitzgerald began coverage on shares of InflaRx (NASDAQ:IFRX) in a research note published on Tuesday, MarketBeat reports. The firm issued an overweight rating and a $10.00 price target on the stock. Cantor Fitzgerald also issued estimates for InflaRx’s FY2025 earnings at ($0.87) EPS.

A number of other equities research analysts have also weighed in on the company. Guggenheim lifted their target price on InflaRx from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, March 26th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of InflaRx in a research note on Friday, March 21st.

InflaRx Trading Up 8.8 %

NASDAQ:IFRX opened at $1.85 on Tuesday. The company has a market cap of $124.20 million, a price-to-earnings ratio of -1.71 and a beta of 2.21. InflaRx has a twelve month low of $0.82 and a twelve month high of $2.82. The stock has a fifty day simple moving average of $1.20 and a 200-day simple moving average of $1.82.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. As a group, equities research analysts predict that InflaRx will post -1.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Two Sigma Securities LLC purchased a new position in InflaRx in the fourth quarter valued at about $28,000. Geode Capital Management LLC lifted its position in shares of InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after buying an additional 11,900 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of InflaRx by 20.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock valued at $275,000 after buying an additional 19,000 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of InflaRx in the 4th quarter worth approximately $51,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of InflaRx in the 4th quarter worth approximately $55,000. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.